Luye Pharma Group Ltd.

SEHK:2186 Voorraadrapport

Marktkapitalisatie: HK$9.9b

Luye Pharma Group Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Dian Bo Liu

Algemeen directeur

CN¥4.2m

Totale compensatie

Percentage CEO-salaris75.1%
Dienstverband CEO21.3yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn12.8yrs
Gemiddelde ambtstermijn bestuur10.4yrs

Recente managementupdates

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21
We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Recent updates

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Sep 25
Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Aug 29
Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Jun 19
Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21
We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Apr 26
Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Feb 29
Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Jan 09
Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

Dec 19
Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Nov 24
A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Is Luye Pharma Group (HKG:2186) A Risky Investment?

Sep 12
Is Luye Pharma Group (HKG:2186) A Risky Investment?

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Aug 17
Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

May 10
Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Sep 20
We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook

Apr 06
Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook

Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares

Mar 17
Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares

Analyse CEO-vergoeding

Hoe is Dian Bo Liu's beloning veranderd ten opzichte van Luye Pharma Group's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

CN¥770m

Mar 31 2024n/an/a

CN¥652m

Dec 31 2023CN¥4mCN¥3m

CN¥533m

Sep 30 2023n/an/a

CN¥495m

Jun 30 2023n/an/a

CN¥458m

Mar 31 2023n/an/a

CN¥531m

Dec 31 2022CN¥3mCN¥3m

CN¥605m

Sep 30 2022n/an/a

CN¥190m

Jun 30 2022n/an/a

-CN¥224m

Mar 31 2022n/an/a

-CN¥179m

Dec 31 2021CN¥4mCN¥3m

-CN¥134m

Sep 30 2021n/an/a

CN¥210m

Jun 30 2021n/an/a

CN¥554m

Mar 31 2021n/an/a

CN¥630m

Dec 31 2020CN¥5mCN¥4m

CN¥707m

Sep 30 2020n/an/a

CN¥955m

Jun 30 2020n/an/a

CN¥1b

Mar 31 2020n/an/a

CN¥1b

Dec 31 2019CN¥4mCN¥3m

CN¥1b

Sep 30 2019n/an/a

CN¥1b

Jun 30 2019n/an/a

CN¥1b

Mar 31 2019n/an/a

CN¥1b

Dec 31 2018CN¥4mCN¥3m

CN¥1b

Sep 30 2018n/an/a

CN¥1b

Jun 30 2018n/an/a

CN¥1b

Mar 31 2018n/an/a

CN¥1b

Dec 31 2017CN¥4mCN¥3m

CN¥981m

Compensatie versus markt: De totale vergoeding ($USD 577.24K ) Dian Bo } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 487.93K ).

Compensatie versus inkomsten: De vergoeding van Dian Bo is het afgelopen jaar met meer dan 20% gestegen.


CEO

Dian Bo Liu (58 yo)

21.3yrs

Tenure

CN¥4,180,000

Compensatie

Mr. Dian Bo Liu is a Co-Founder of Luye Pharma Group Ltd. in 1994 and serves as its Head of Corporate Directions & Strategies and has been its Chief Executive Officer since July 2003. Mr. Liu is responsibl...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Dian Bo Liu
Co-Founder21.3yrsCN¥4.18mgeen gegevens
Rong Bing Yang
Co-Founder & Vice Executive Chairman21.3yrsCN¥3.09mgeen gegevens
Hui Xian Yuan
Co-Founder & Executive Directorno dataCN¥1.46mgeen gegevens
Yuan Yuan Zhu
Executive Directorno dataCN¥1.50mgeen gegevens
Yuan Chong Liu
Chief Financial Officer12.8yrsgeen gegevensgeen gegevens
Mei Yi Lee
Company Secretary3.9yrsgeen gegevensgeen gegevens

12.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2186 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 12.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Dian Bo Liu
Co-Founder21.3yrsCN¥4.18mgeen gegevens
Rong Bing Yang
Co-Founder & Vice Executive Chairman21.3yrsCN¥3.09mgeen gegevens
Hui Xian Yuan
Co-Founder & Executive Director21.3yrsCN¥1.46mgeen gegevens
Yuan Yuan Zhu
Executive Director10.7yrsCN¥1.50mgeen gegevens
Yuk Lam Lo
Independent Non-Executive Director10.4yrsCN¥269.00kgeen gegevens
Man Kit Leung
Independent Non-Executive Director10.4yrsCN¥322.00kgeen gegevens
Rui Lin Song
Non-Executive Director7.7yrsCN¥269.00kgeen gegevens
Sze Chung Choy
Independent Non-Executive Director10.4yrsCN¥269.00kgeen gegevens
Huaqiao Zhang
Independent Non-Executive Director10.4yrsCN¥269.00kgeen gegevens
Dong Lyu
Non-Executive Directorless than a yeargeen gegevensgeen gegevens
Lian Xia
Independent Non-Executive Director1.5yrsCN¥162.00kgeen gegevens

10.4yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2186 zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.4 jaar).